These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7242249)

  • 1. Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain.
    Theodorou A; Gommeren W; Clow A; Leysen J; Jenner P; Marsden CD
    Life Sci; 1981 Apr; 28(14):1621-7. PubMed ID: 7242249
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.
    Dawbarn D; Pycock C
    Eur J Pharmacol; 1981 May; 71(2-3):233-45. PubMed ID: 6113967
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum.
    Murugaiah K; Theodorou A; Mann S; Clow A; Jenner P; Marsden CD
    Nature; 1982 Apr; 296(5857):570-2. PubMed ID: 6122161
    [No Abstract]   [Full Text] [Related]  

  • 4. The residual effect of chronic neuroleptic treatment on the neuroleptic binding assay in rats.
    Wan CW; Peck EJ; Ho BT; Schoolar JC
    Life Sci; 1983 Mar; 32(11):1255-62. PubMed ID: 6834989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated administration of U-50,488H on the binding of 3H-SCH 23390 and 3H-spiperone to rat brain and spinal cord dopamine receptors.
    Bhargava HN; Ramarao P; Gulati A
    Prog Clin Biol Res; 1990; 328():153-6. PubMed ID: 2406759
    [No Abstract]   [Full Text] [Related]  

  • 6. Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Nature; 1979 Mar; 278(5699):59-61. PubMed ID: 570253
    [No Abstract]   [Full Text] [Related]  

  • 7. Detection of multiple receptors for dopamine.
    Spano PF; Memo M; Stefanini E; Fresia P; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 21():243-51. PubMed ID: 7376971
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of hypophysectomy-induced dopamine receptor hypersensitivity in male rats by chronic haloperidol administration.
    Gordon JH; Diamond BI
    J Neurochem; 1984 Feb; 42(2):523-8. PubMed ID: 6537969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine.
    Janowsky A; Neve KA; Kinzie JM; Taylor B; de Paulis T; Belknap JK
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1282-90. PubMed ID: 1534844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional changes in brain dopamine receptor function during six months trifluoperazine administration to rats [proceedings].
    Clow A; Jenner P; Marsden CD; Theodorou A
    Br J Pharmacol; 1980 Jan; 68(1):163P-164P. PubMed ID: 7357176
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo studies of dopamine receptor ontogeny.
    Murrin LC
    Life Sci; 1982 Sep; 31(10):971-80. PubMed ID: 7132558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 14. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic drugs and the dopamine hypothesis.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Lancet; 1979 Apr; 1(8122):934. PubMed ID: 86713
    [No Abstract]   [Full Text] [Related]  

  • 16. 77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors.
    Owen F; Poulter M; Mashal RD; Crow TJ; Veall N; Zanelli GD
    Life Sci; 1983 Aug; 33(8):765-8. PubMed ID: 6888192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings].
    Clow A; Jenner P; Marsden CD
    Br J Pharmacol; 1978 Nov; 64(3):414P. PubMed ID: 719266
    [No Abstract]   [Full Text] [Related]  

  • 18. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.
    Bischoff S; Heinrich M; Sonntag JM; Krauss J
    Eur J Pharmacol; 1986 Oct; 129(3):367-70. PubMed ID: 3536532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]Spiperone labels non-cyclase-linked dopamine receptors in the ventral tegmental area of rat brain.
    Gundlach AL; McDonald D; Beart PM
    J Neurochem; 1982 Sep; 39(3):890-4. PubMed ID: 7097294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.